Recently, we found that daily administration of sucralose (delivered in the commercial product Splenda at sucralose dosages approved for use by global regulatory agencies) over a 12-week period to rats produced highly significant reductions in the numbers of total anaerobes, bifidobacteria, lactobacilli, Bacteroides , clostridia, and total aerobic bacteria with no significant treatment effect on enterobacteria ( Abou-Donia et al. 2008 ).
← all excerpts
Rationale for further medical and health research on high-potency sweeteners.
1
—
—